Navigation Links
Abbott Completes Acquisition of STARLIMS Technologies

ABBOTT PARK, Ill., March 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems.  

The acquisition provides Abbott with leading products and expertise to build its position in laboratory informatics, an emerging and rapidly growing field focused on helping to manage the increasing amount of data generated in laboratories. STARLIMS's advanced web-based software applications help laboratories efficiently store, retrieve and analyze data and are designed for a wide variety of laboratory environments operating across a number of scientific, industrial and clinical disciplines.  

"STARLIMS gives us access to innovative technologies and technical expertise for our long-term strategy in laboratory informatics," said Edward L. Michael, executive vice president, diagnostics products, Abbott. "The acquisition enables us to provide a common informatics framework across all of our diagnostics businesses and, equally important, will help accelerate STARLIMS's growth strategy in the non-diagnostics market segments it currently serves."

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
2. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
3. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
4. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
5. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
6. Abbott to Present at Cowen and Company Annual Health Care Conference
7. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
8. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
9. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
10. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
11. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
Post Your Comments:
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds ... critical that the first impression be positive and reflects business values. If a client ... anything or want to return. They will also share their thoughts about a business ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin ... System. Brillouin is the developer of renewable energy technologies capable of producing commercially ... (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor core modules ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... is pleased to welcome Winter-Dent & Company as its newest Partner Firm. Based ... to become a client's most trusted advisor regardless of whether that client is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
Breaking Medicine News(10 mins):